Cericare products were showcased at the Chinese Orthopaedic Association (COA) 2025 and received high recognition from the industry.

In November 2025, the Chinese Orthopaedic Association (COA) —China’s most authoritative orthopedic Conference—was grandly held in Tianjin. Cericare Company showcased its independently developed hip joint ceramic femoral head (consistent with prior "femoral head" terminology for orthopedic implants). Owing to its exceptional product performance and high clinical application value, the product won unanimous praise from on-site experts, medical professionals, and industry clients, and emerged as one of the exhibition’s highlights.

As China’s premier academic and industrial exchange platform in the orthopedic field, this year’s COA Conference brought together top orthopedic experts from home and abroad, representatives of medical institutions, and enterprises across the industrial chain. Together, they showcased cutting-edge technologies and innovative achievements in orthopedics.

Cericare Medical is an enterprise with years of deep expertise in the field of medical ceramic materials—showcased a hip joint ceramic femoral head at the exhibition. Leveraging advanced silicon nitride ceramic preparation technology, this product integrates core advantages including high hardness, exceptional wear resistance, and excellent biocompatibility. Its wear rate is only one-tenth that of traditional metal materials, and it can effectively prevent bone dissolution caused by the release of metal ions—significantly extending the service life of prostheses.

At the exhibition venue, Cericare product display area drew a large number of visitors who stopped to inquire. The company’s professional team elaborated on the product’s R&D process, performance metrics, and clinical application cases in detail, enabling participants to gain an in-depth understanding of the product’s outstanding value in improving the efficacy of hip replacement surgery and enhancing patients’ postoperative quality of life. After witnessing the product demonstration firsthand, many orthopedic experts spoke highly of its precision craftsmanship and stable performance. They noted that this product offers a higher-quality option for clinical treatment and is expected to drive the upgrading and iteration of domestic high-end orthopedic implants. 

This participation in COA 2025 not only demonstrated Cericare’s technological innovation capabilities, but also built a bridge for in-depth exchanges with industry peers. Looking ahead, Cericare will continue to focus on technological Research and Development, support the advancement of orthopedic care with more competitive products, and enable domestic medical ceramic technology to benefit a broader range of patients.